Molecular Imaging Insight - May 2008 - (Page 1) Molecular Imaging Insight Editor Johannes Czernin, MD David Geffen School of Medicine at UCLA Editor@MolecularImaging.net Editorial Mary C. Tierney, Editorial Director mtierney@trimedmedia.com Beth Walsh, Senior Editor bwalsh@trimedmedia.com Lisa Fratt, Features Writer lfratt@trimedmedia.com Jonathan Batchelor, Web Editor jbatchelor@trimedmedia.com Justine Cadet, News Editor jcadet@trimedmedia.com Sarah Lamberti, Assistant News Editor slamberti@trimedmedia.com Contributing Editor Rodney J. Hicks, MD, FRACP Interactive Media Amy Lizotte, Interactive Media Manager alizotte@trimedmedia.com Jeff Hill, Interactive Media Developer jhill@trimedmedia.com Art & Design Michele Rivera, Art Director mrivera@trimedmedia.com Jason Litchfield, Production Editor jlitchfield@trimedmedia.com Administration Kristen Bouthillier, Business Manager kbouthillier@trimedmedia.com 401.383.5660, ext. 200 Publisher Jack Spears jspears@trimedmedia.com 401.383.5660, ext. 202 Editorial Submissions & Information Editorial@MolecularImaging.net Subscriptions Subs@MolecularImaging.net Creative Services & Information Art@MolecularImaging.net Corporate Office 235 Promenade Street, Suite 455 Providence, Rhode Island 02908 tel. 401.383.5660 fax 401.383.3896 Sponsored by an educational grant from: table of contents May 008 – Vol. 2 No. 3 MolecularImaging.net COVER STORY 03 Breast Cancer: When Molecular Imaging is the Right Choice Whole-body FDG-PET and PET/CT are helpful in guiding breast cancer treatment decisions in specific situations, particularly in “staging advanced breast cancer and monitoring systemic response to therapy,” says David Mankoff, MD, PhD, an associate professor of radiology at the University of Washington School of Medicine in Seattle. By Lisa Fratt FROM THE EDITOR 02 NOPR: A Landmark Study By Johannes Czernin, MD SPECIAL REPORT 06 NOPR Delivers Evidence for Expanded PET Use in Oncology Imaging Just-released data gathered from nearly 23,000 cancer patients through the National Oncologic PET Registry (NOPR) show that diagnostic findings from FDG-PET changed patient management in more than one third of patients. Several clinical associations are now pushing CMS to expand reimbursement across a broader list of cancer indications. By Jonathan Batchelor FEATURED ARTICLES 08 Can We Afford Not to Use FDG-PET? By Rodney J. Hicks, MD, FRACP Molecular Imaging Insight (ISSN 1941-0549) is published quarterly by TriMed Media Group, Inc. Copyright © 2008 by TriMed Media Group, Inc. All rights reserved. Reproduction in any form is forbidden without permission. The information, opinions and statements expressed in the articles and advertisements herein are those of the writer and/or advertiser. Molecular Imaging Insight and Siemens Medical make no representation as to the accuracy or completeness of the information contained in the articles. Siemens’ sponsorship is not intended to convey endorsement of or affiliation with the authors. 11 Pint-size Power: PET/CT and SPECT/CT in Pediatrics By Sarah Lamberti 14 PET/CT in Evolution By Lisa Fratt 16 PET/CT & Next-Generation Radiation Therapy By Lisa Fratt 20 MR/PET: New Insights into Hybrid Imaging By Lisa Fratt ON THE COVER: Breast cancer PET•CT images courtesy of Siemens. MolecularImaging.net May 2008 | Molecular Imaging Insight 1 http://MolecularImaging.net http://MolecularImaging.net
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.